LifeMD (LFMD) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LFMD SEC filings page.
LifeMD, Inc. (LFMD) reported $191.6M in revenue over the twelve months to Jun 30, 2026, up 19.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
LifeMD is scaling revenue while nearing operating break-even, but 2025 accounting profit converted only partly into operating cash.
Revenue grew25.3% while selling, general and administrative costs grew12.5% in FY2025, narrowing the operating loss even though it remained negative. Net income reached$14.4M , but operating cash flow represented only57.7% of reported profit, so earnings did not translate one-for-one into cash.
Free cash flow fell
Equity moved from negative
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of LifeMD, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
LifeMD, Inc. has an operating margin of -4.0%, meaning the company loses $4 on every $100 of revenue. This results in a profitability score of 26/100. This is up from -13.2% the prior year.
LifeMD, Inc.'s revenue surged 25.3% year-over-year to $194.1M, reflecting rapid business expansion. This strong growth earns a score of 71/100.
LifeMD, Inc.'s current ratio of 1.25 indicates adequate short-term liquidity, earning a score of 31/100. The company can meet its near-term obligations, though with limited headroom.
LifeMD, Inc. has a free cash flow margin of 3.3%, earning a moderate score of 50/100. The company generates positive cash flow after capital investments, but with room for improvement.
LifeMD, Inc. generates a 62.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 16/100.
LifeMD, Inc. scores -0.61, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $228.6M against total assets of $70.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
LifeMD, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, LifeMD, Inc. generates $0.58 in operating cash flow ($8.3M OCF vs $14.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
LifeMD, Inc. reported an operating loss of $7.7M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
LifeMD, Inc. generated $47.3M in revenue in Q2 2026. This represents a decrease of 3.5% from the same quarter a year earlier. Against the prior quarter it is down 5.7%.
LifeMD, Inc.'s EBITDA was -$6.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
LifeMD, Inc. reported a net loss of $7.1M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
LifeMD, Inc. earned -$0.16 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
LifeMD, Inc. recorded an outflow of $7.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 188.9% from the same quarter a year earlier. Against the prior quarter it is down 2160.3%.
LifeMD, Inc. held $25.1M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
LifeMD, Inc.'s gross margin was 88.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
LifeMD, Inc.'s operating margin was -15.1% in Q2 2026, reflecting core business profitability. This is down 10.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.7 percentage points.
LifeMD, Inc.'s net profit margin was -15.0% in Q2 2026, showing the share of revenue converted to profit. This is down 11.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.7 percentage points.
LifeMD, Inc.'s quarterly ROE was -88.9% in Q2 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is down 29.9 percentage points.
Capital Allocation
LifeMD, Inc. invested $68K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 91.3% from the same quarter a year earlier. Against the prior quarter it is down 35.5%.
Not reported for Q2 2026.
Not reported for Q2 2026.
LFMD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.3M-3.5% | $50.2M-1.4% | $34.0M+403.7% | $60.2M+13.0% | $49.0M-3.2% | $50.9M+15.3% | $6.7M-85.0% | $53.3M+38.0% |
| Cost of Revenue | $5.3M-22.7% | $5.9M-27.2% | $5.3M-21.6% | $7.4M+47.8% | $6.8M+36.1% | $8.1M+76.9% | $6.8M+27.0% | $5.0M+4.9% |
| Gross Profit | $42.0M-0.4% | $44.2M+3.5% | $28.6Mn/m | $52.8M+9.3% | $42.2M-7.6% | $42.8M+8.1% | -$56K-100.1% | $48.3M+42.6% |
| SG&A Expenses | $41.7M+13.9% | $45.1M+23.0% | $24.7Mn/m | $46.1M+3.0% | $36.6M-18.5% | $36.6M-7.3% | -$1.1M-102.9% | $44.7M+34.8% |
| Operating Income | -$7.1Mn/m | -$8.9Mn/m | -$2.2Mn/m | -$2.0Mn/m | -$2.3Mn/m | -$1.2Mn/m | -$3.9Mn/m | -$4.0Mn/m |
| EBITDA | -$6.8Mn/m | -$8.6Mn/m | -$2.1Mn/m | -$1.4Mn/m | -$2.1Mn/m | -$1.0Mn/m | -$4.5Mn/m | -$3.6Mn/m |
| Interest Expense | -$46K-106.9% | -$56K-112.2% | -$26K-104.3% | $262K-53.0% | $661K+24.3% | $464K-2.9% | $608K-2.4% | $559K-21.7% |
| Income Tax | N/A | N/A | N/A | $169K-27.3% | N/A | N/A | N/A | $233K |
| Net Income | -$7.1Mn/m | -$8.9Mn/m | $20.0Mn/m | -$3.8Mn/m | -$1.6Mn/m | -$184Kn/m | -$3.1Mn/m | -$4.7Mn/m |
| EPS (Basic) | -$0.16n/m | -$0.20 | -$0.12n/m | -$0.10n/m | -$0.05n/m | -$0.02 | -$0.14n/m | -$0.13n/m |
| EPS (Diluted) | -$0.16n/m | -$0.20 | -$0.12n/m | -$0.10n/m | -$0.05n/m | -$0.02 | -$0.14n/m | -$0.13n/m |
| Diluted Shares (Avg) | 48M+7.6% | 47M | N/A | 46M+9.9% | 44M+7.5% | 43M | N/A | 42M+21.9% |
Not reported in any period shown, so not listed: R&D Expenses.
LFMD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $59.9M-18.6% | $70.1M-4.7% | $70.4M-7.5% | $66.0M-9.1% | $73.6M+15.3% | $73.6M+19.8% | $76.1M+30.1% | $72.6M+78.3% |
| Current Assets | $42.1M-14.2% | $51.7M+3.5% | $51.8M-1.0% | $41.1M-15.6% | $49.0M+8.8% | $50.0M+12.5% | $52.4M+22.9% | $48.7M+95.5% |
| Cash & Equivalents | $25.1M-30.6% | $34.5M+0.2% | $36.8M+5.1% | $23.8M-36.7% | $36.2M+1.5% | $34.4M-2.0% | $35.0M+5.6% | $37.6M+145.9% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $3.0M-9.1% | $3.2M+7.1% | $2.8M-0.9% | $3.4M+29.7% | $3.3M+57.8% | $3.0M+25.0% | $2.8M+1.4% | $2.6M-30.2% |
| Accounts Receivable | $11.3M+53.6% | $9.9M-3.3% | $9.3M-11.0% | $9.2M+52.8% | $7.3M+29.3% | $10.2M+91.0% | $10.5M+66.9% | $6.0M+36.9% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $51.9M-29.0% | $55.1M-25.6% | $47.3M-43.5% | $62.6M-20.3% | $73.2M+11.1% | $74.0M+23.0% | $83.7M+58.1% | $78.5M+51.6% |
| Current Liabilities | $46.6M-26.6% | $49.6M-18.6% | $41.6M-38.3% | $56.7M-3.9% | $63.5M+23.0% | $60.9M+36.3% | $67.4M+93.8% | $59.0M+81.3% |
| Non-Current Liabilities | $5.3M-44.9% | $5.5M-58.0% | $5.7M-65.0% | $6.0M-69.6% | $9.7M-32.2% | $13.1M-15.3% | $16.3M-10.4% | $19.6M+1.6% |
| Long-Term Debt | N/A | N/A | N/A | N/A | $15.9M+34.8% | $6.8M-51.5% | $9.9M-44.9% | $13.0M-31.2% |
| Total Equity | $8.0Mn/m | $15.0Mn/m | $23.2Mn/m | $1.3Mn/m | -$1.8Mn/m | -$2.3Mn/m | -$9.1M-359.1% | -$7.7Mn/m |
| Retained Earnings | -$246.1Mn/m | -$238.3Mn/m | -$228.6Mn/m | -$247.8Mn/m | -$238.5Mn/m | -$235.6Mn/m | -$239.9Mn/m | -$235.4Mn/m |
Not reported in any period shown, so not listed: Goodwill.
LFMD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.9M-180.2% | $445K-85.5% | -$3.3M-405.6% | -$147K-102.2% | $8.6M+90.3% | $3.1M-41.0% | $1.1M-81.2% | $6.7M+522.4% |
| Depreciation & Amortization | $325K+63.3% | $321K+98.3% | -$425Kn/m | $548K+37.8% | $199K-43.2% | $162K-48.0% | -$567K-286.8% | $397K+34.3% |
| Stock-Based Compensation | N/A | $1.4M-43.1% | N/A | N/A | N/A | $2.5M+0.2% | N/A | N/A |
| Capital Expenditures | $68K-91.3% | $105K-10.5% | $155K-21.5% | $821K+83.3% | $777K+21.0% | $118K-33.1% | $198K+81.0% | $448K+1379.7% |
| Free Cash Flow | -$7.0M-188.9% | $339K-88.5% | -$3.4M-492.5% | -$968K-115.5% | $7.9M+101.7% | $3.0M-41.3% | $875K-84.4% | $6.3M+497.6% |
| Investing Cash Flow | -$1.6Mn/m | -$2.1Mn/m | $17.1Mn/m | -$3.6Mn/m | -$3.7Mn/m | -$2.9Mn/m | -$2.7Mn/m | -$3.5Mn/m |
| Financing Cash Flow | -$777Kn/m | -$696Kn/m | -$789Kn/m | -$8.7Mn/m | -$3.1Mn/m | -$813Kn/m | -$935K-106.5% | -$1.3M-128.0% |
| Dividends Paid | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% |
| Share Buybacks | N/A | N/A | N/A | $270K | N/A | N/A | N/A | N/A |
LFMD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.8%+2.8pp | 88.2%+4.2pp | 84.3%+85.1pp | 87.7%-2.9pp | 86.1%-4.0pp | 84.0%-5.6pp | -0.8%-88.9pp | 90.6%+3.0pp |
| Operating Margin | -15.1%-10.3pp | -17.8%-15.5pp | -6.4%+51.9pp | -3.3%+4.2pp | -4.8%+7.7pp | -2.3%+11.7pp | -58.2%-53.4pp | -7.5%+4.3pp |
| Net Margin | -15.0%-11.7pp | -17.7%-17.3pp | 58.8%+104.8pp | -6.3%+2.4pp | -3.3%+10.3pp | -0.4%+15.0pp | -46.1%-37.7pp | -8.7%+7.1pp |
| Return on Equity | -88.9% | -59.0% | 86.2% | -289.6% | N/A | N/A | N/A | N/A |
| Return on Assets | -11.8%-9.6pp | -12.7%-12.4pp | 28.3%+32.4pp | -5.8%+0.6pp | -2.2%+8.6pp | -0.3%+10.8pp | -4.1%+2.3pp | -6.4%+8.6pp |
| Current Ratio | 0.90+0.1x | 1.04+0.2x | 1.25+0.5x | 0.73-0.1x | 0.77-0.1x | 0.82-0.2x | 0.78-0.4x | 0.83+0.1x |
| Liabilities-to-Equity | 6.52 | 3.66 | 2.04 | 47.64 | N/A | N/A | N/A | N/A |
| Asset Turnover | 0.79+0.1x | 0.720.0x | 0.48+0.4x | 0.91+0.2x | 0.67-0.1x | 0.690.0x | 0.09-0.7x | 0.73-0.2x |
| FCF Margin | -14.8%-30.8pp | 0.7%-5.1pp | -10.1%-23.1pp | -1.6%-13.3pp | 16.0%+8.3pp | 5.8%-5.6pp | 13.0%+0.5pp | 11.7%+9.0pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| LifeMD, Inc. LFMD | FY2025 | $194.1M | $14.4M | 7.4% | $107.6M | 37/100 |
| Mobile-health Network Solutions MNDR | FY2025 | $7.6M | -$3.4M | -44.3% | $1.1M | 31/100 |
| Health Catalyst, Inc HCAT | FY2025 | $311.1M | -$178.0M | -57.2% | $118.2M | 38/100 |
| SOPHiA GENETICS SA SOPH | FY2025 | $77.3M | -$79.0M | N/A | $641.9M | 60/100 |
| CareCloud, Inc. CCLD | FY2025 | $120.5M | $10.8M | 9.0% | $73.9M | 45/100 |
Where LifeMD, Inc. Ranks
Frequently Asked Questions
What is LifeMD, Inc.'s annual revenue?
LifeMD, Inc. (LFMD) reported $194.1M in total revenue for fiscal year 2025. This represents a 25.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is LifeMD, Inc.'s revenue growing?
LifeMD, Inc. (LFMD) revenue grew by 25.3% year-over-year, from $154.8M to $194.1M in fiscal year 2025.
Is LifeMD, Inc. profitable?
Yes, LifeMD, Inc. (LFMD) reported a net income of $201K over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $14.4M, with a net profit margin of 7.4%.
What is LifeMD, Inc.'s EBITDA?
LifeMD, Inc. (LFMD) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is LifeMD, Inc.'s gross margin?
LifeMD, Inc. (LFMD) had a gross margin of 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is LifeMD, Inc.'s operating margin?
LifeMD, Inc. (LFMD) had an operating margin of -4.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is LifeMD, Inc.'s net profit margin?
LifeMD, Inc. (LFMD) had a net profit margin of 7.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is LifeMD, Inc.'s return on equity (ROE)?
LifeMD, Inc. (LFMD) has a return on equity of 62.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is LifeMD, Inc.'s free cash flow?
LifeMD, Inc. (LFMD) generated $6.4M in free cash flow during fiscal year 2025. This represents a -60.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is LifeMD, Inc.'s operating cash flow?
LifeMD, Inc. (LFMD) generated $8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are LifeMD, Inc.'s total assets?
LifeMD, Inc. (LFMD) had $70.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are LifeMD, Inc.'s capital expenditures?
LifeMD, Inc. (LFMD) invested $1.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is LifeMD, Inc.'s current ratio?
LifeMD, Inc. (LFMD) had a current ratio of 1.25 as of fiscal year 2025, which is considered adequate.
What is LifeMD, Inc.'s liabilities-to-equity ratio?
LifeMD, Inc. (LFMD) had a liabilities-to-equity ratio of 2.04 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is LifeMD, Inc.'s return on assets (ROA)?
LifeMD, Inc. (LFMD) had a return on assets of 20.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is LifeMD, Inc.'s P/E ratio?
LifeMD, Inc. (LFMD) trades at 535x earnings, its market capitalization divided by $201K net income, trailing 12 months to June 30, 2026. The market capitalization is $107.6M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is LifeMD, Inc.'s price-to-sales ratio?
LifeMD, Inc. (LFMD) trades at 0.6x sales, its market capitalization divided by $191.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $107.6M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is LifeMD, Inc.'s Altman Z-Score?
LifeMD, Inc. (LFMD) has an Altman Z-Score of -0.61, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is LifeMD, Inc.'s Piotroski F-Score?
LifeMD, Inc. (LFMD) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are LifeMD, Inc.'s earnings high quality?
LifeMD, Inc. (LFMD) has an earnings quality ratio of 0.58x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can LifeMD, Inc. cover its interest payments?
LifeMD, Inc. (LFMD) reported an operating loss of $7.7M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is LifeMD, Inc.?
LifeMD, Inc. (LFMD) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.